<DOC>
	<DOCNO>NCT00003796</DOCNO>
	<brief_summary>Phase II trial study effectiveness irofulven treat patient metastatic breast cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Irofulven Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate time treatment failure patient refractory metastatic adenocarcinoma breast treat irofulven . II . Assess qualitative quantitative toxic effect drug patient . III . Determine population pharmacokinetics pharmacokinetics-pharmacodynamic relationship drug patient . OUTLINE : This multicenter study . Patients receive irofulven IV 30 minute day 1 15 . Treatment continue every 28 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma breast Measurable disease outside previously irradiate area occurred/progressed completion radiotherapy Must receive 1 2 prior chemotherapy regimens metastatic disease More 3 prior regimen allow No active brain metastasis meningeal breast cancer involvement PATIENT CHARACTERISTICS : Sex : Male female Performance status : SWOG 02 Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 3 time ULN ( 5 time ULN liver metastasis ) Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No history myocardial infarction unstable angina within past 6 month No uncontrolled congestive heart failure Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Prior diagnosis cancer allow ( must cancer therapy evidence disease ) No history retinopathy and/or macular degeneration PRIOR CONCURRENT THERAPY : Chemotherapy : No prior irofulven</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>